
  <style>
  .gh-table table { 
    border-collapse: collapse; 
    width: 100%;
    border: 1px solid #444;
    font-size: 12px;
  }
  .gh-table th, .gh-table td { 
    border: 1px solid #444; 
    padding: 4px 6px; 
    vertical-align: top;
    font-weight: 400 !important;   /* regular font */
  }
  .gh-table th { 
    .gh-table th { background: #f5f5f5; text-align: left; }
  }
  .gh-table th { font-weight: 700 !important; }
    @media print {
      .gh-table { font-size: 10px; }
    }
  </style>
  <div class='gh-table'><table><thead><tr><th>Molecola (1)</th><th>Molecola (2)</th><th>description</th></tr></thead><tbody><tr><td>Canrenoic acid</td><td>Abacavir</td><td>Canrenoic acid may increase the excretion rate of Abacavir which could result in
a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Canrenoic acid</td><td>Furosemide</td><td>Canrenoic acid may increase the excretion rate of Furosemide which could result
in a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Canrenoic acid</td><td>Insulin glargine</td><td>The therapeutic efficacy of Insulin glargine can be decreased when used in
combination with Canrenoic acid.</td></tr><tr><td>Canrenoic acid</td><td>Insulin glulisine</td><td>The therapeutic efficacy of Insulin glulisine can be decreased when used in
combination with Canrenoic acid.</td></tr><tr><td>Furosemide</td><td>Abacavir</td><td>Furosemide may decrease the excretion rate of Abacavir which could result in a
higher serum level.</td></tr><tr><td>Furosemide</td><td>Insulin glargine</td><td>The risk or severity of hypoglycemia can be increased when Furosemide is
combined with Insulin glargine.</td></tr><tr><td>Furosemide</td><td>Insulin glulisine</td><td>The risk or severity of hypoglycemia can be increased when Furosemide is
combined with Insulin glulisine.</td></tr><tr><td>Insulin glulisine</td><td>Insulin glargine</td><td>The risk or severity of hypoglycemia can be increased when Insulin glargine is
combined with Insulin glulisine.</td></tr><tr><td>Lamivudine</td><td>Canrenoic acid</td><td>Canrenoic acid may increase the excretion rate of Lamivudine which could result
in a lower serum level and potentially a reduction in efficacy.</td></tr><tr><td>Lamivudine</td><td>Furosemide</td><td>Furosemide may decrease the excretion rate of Lamivudine which could result in a
higher serum level.</td></tr><tr><td>Omeprazole</td><td>Raltegravir</td><td>Omeprazole can cause an increase in the absorption of Raltegravir resulting in
an increased serum concentration and potentially a worsening of adverse effects.</td></tr></tbody></table></div>
